🇺🇸·5d agoIndustry
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
Publisher
B
Bristol-Myers Squibb News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on bristolmyers2016ir.q4web.com
Leave the platform to read the original full article on the publisher site.
Source: Bristol-Myers Squibb News
Scope: Industry
Related coverage
More related coverage
Ipsen·9h ago
Choosing the hardest problems: why Ipsen focuses where unmet need is greatest
Ipsen RSS·9h ago
Choosing the hardest problems: why Ipsen focuses where unmet need is greatest
Hyman, Phelps & McNamara (FDA Law)·16h ago
FDA Issues Final Guidance for Content of Human Factors Information in Medical Device Submissions
Natco Pharma·17h ago